Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
NLS Pharmaceutics ( (NLSP) ) just unveiled an update.
NLS Pharmaceutics announced substantial progress in its Dual Orexin Receptor Agonist (DOXA) platform for treating sleep and neurodegenerative diseases, with promising results from preclinical studies on compounds AEX-41 and AEX-2. The company is also preparing for a transformative merger with Kadimastem Ltd., which will enhance its development pipeline and financial position, while ensuring compliance with Nasdaq listing requirements and strengthening its balance sheet through financial restructuring and private placements.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a global development-stage biopharmaceutical company based in Switzerland, founded in 2015. It focuses on discovering and developing innovative therapies for rare and complex central nervous system disorders, working with world-class partners and scientists.
YTD Price Performance: -91.61%
Average Trading Volume: 305,714
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.9M
For an in-depth examination of NLSP stock, go to TipRanks’ Stock Analysis page.
